What Rebecca's Reading
- 'Serpent-Handling' West Virginia Pastor Dies From Snake Bite A “serpent-handling” West Virginia pastor died after his rattlesnake bit him during a church ritual, just as the man had apparently watched a snake kill his father years before.
- A Dispute Over Who Owns a Twitter Account Goes to Court How much is a tweet worth? And how much does a Twitter follower cost?
- A dollar badly spent: New facts on processed food in school lunches In a collaboration between The New York Times and the Investigative Fund, reporter Lucy Komisar delved into the billion-dollar business of the national school lunch program and found some unsettling news.
Archives by Date:
- July 2020
- April 2017
- January 2017
- August 2016
- December 2015
- September 2013
- June 2013
- May 2012
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
Archives by Subject:
- Animals
- Appearances
- Assistance Creatures
- Bioethics
- Book Related
- Book Reviewing
- Cervical Cancer
- Disability Rights
- Education
- From the Archives
- Genetic Privacy
- HeLa
- HeLa FAQs
- History of Science and Medicine
- Housekeeping
- HPV
- Infertility Treatments
- Media Appearances
- Media Watch
- Medicine & Health
- Neurology
- News
- Paperback Edition
- Personal
- Policy
- Politics
- Press
- Publication News and Followups
- Publishing
- Race and Medicine
- Reviews
- Science & Money
- Science Writing
- Sketchy Science
- Testimonials
- The Henrietta Lacks Foundation
- The Immortal Book Tour
- The Immortal Life of Henrietta Lacks
- Tips
- Toxo
- Uncategorized
- Weird Science
- Women and Science
May 17, 2009
Patent Dispute Prevents Patients From Getting Promising Drug for Lou Gehrig’s Disease
Speaking of the debate over patents interfering with medical care, there’s a story in today’s New York Times that mentions the drug Iplex, which has shown promise for treating Lou Gehrig’s disease — a deadly and thus far untreatable degenerative disease (also known as amyotrophic lateral sclerosis).
From the article:
Iplex … is believed to protect the motor neurons whose
death leads to paralysis in A.L.S. Some patients had persuaded their
doctors to prescribe the drug when the F.D.A. approved it in late 2006
for children with growth deficiencies. “I started on Tuesday,” Debbie Gattoni, an A.L.S. patient in New Jersey, had written on a Web discussion forum, “and on Sunday, I noticed that my right index finger, which was bent, was straightening and moving on its own.”But
almost immediately, the drug’s maker, Insmed, lost a patent
infringement lawsuit to a biotechnology firm that was already selling a
drug for short stature that had similar properties. Iplex , however, was thought to be more potent for treating A.L.S. Insmed agreed to pull its drug off the market. Only the Italian Health Ministry, which had begun to distribute the drug to A.L.S. patients under a compassionate use program, could continue to buy it … [but] only Italian citizens could receive Iplex through the program.
This situation is quite different from the breast cancer gene patent situation I wrote about in my recent Slate Double X column — the Iplex dispute is over drugs, which are clearly inventions, and no one is questioning the legality of drug patents. But it does raises some relevant questions about the intersection of patents and medical care.
Strict Standards: Only variables should be assigned by reference in /home/n0ld3odkhcxn/public_html/wp-content/plugins/subscribe-to-comments/subscribe-to-comments.php on line 590
Mike Olson says:
I can only agree with what has already been said. But, I figure by posting, I’m rewarding the author with greater response numbers, which in turn will lead to more posts of a similar nature. Thanks for posting this.
Strict Standards: Only variables should be assigned by reference in /home/n0ld3odkhcxn/public_html/wp-content/plugins/subscribe-to-comments/subscribe-to-comments.php on line 590
MMORPG says:
That’s lame, those patients need those durgs, I find it absurd that patents are preventing it.
Strict Standards: Only variables should be assigned by reference in /home/n0ld3odkhcxn/public_html/wp-content/plugins/subscribe-to-comments/subscribe-to-comments.php on line 590
Kevin says:
Thanks for this post. My friend living near the Eiffel Tower may need to look into this. However, I am skeptical at drug companies and their promises. I wonder if this will be another one of those “lifetime treatments” or cures.
Strict Standards: Only variables should be assigned by reference in /home/n0ld3odkhcxn/public_html/wp-content/plugins/subscribe-to-comments/subscribe-to-comments.php on line 590
Julie Simon Lakehomer says:
Hi, again, Rebecca, I’m so glad to read not only this blog entry, but the article in Slate. I was appalled when this gene patenting began with the Human Genome Project. But your Slate article give great reasons why it’s an inhuman practice, and great examples of other such inhuman practices. Problem is the “Bush” Court. Gotta up my ACLU donation.
Strict Standards: Only variables should be assigned by reference in /home/n0ld3odkhcxn/public_html/wp-content/plugins/subscribe-to-comments/subscribe-to-comments.php on line 590
Comrade PhysioProf says:
Sklooty! Come back!
Strict Standards: Only variables should be assigned by reference in /home/n0ld3odkhcxn/public_html/wp-content/plugins/subscribe-to-comments/subscribe-to-comments.php on line 590
Nils Ross says:
I’m not sure I understand. Why isn’t the patent holder simply demanding a cut of the profits, or else manufacturing the drug themselves?
Strict Standards: Only variables should be assigned by reference in /home/n0ld3odkhcxn/public_html/wp-content/plugins/subscribe-to-comments/subscribe-to-comments.php on line 590
Graham Steel says:
Thanks for blogging about this, Rebecca.
May 17, 2009 at 12:52 pm
-
May 17, 2009 at 12:43 pm
« Previous Post
Next Post »
As you say, “it does raise some relevant questions about the intersection of patents and medical care”.
—
An informative link supplied already c/o David which I’ve added to this thread of the ALSTDI Forum:-
Strict Standards: Only variables should be assigned by reference in /home/n0ld3odkhcxn/public_html/wp-content/plugins/subscribe-to-comments/subscribe-to-comments.php on line 590
Rebecca Skloot says:
Huh, that’s interesting. Thanks for posting. Will take a look.
Strict Standards: Only variables should be assigned by reference in /home/n0ld3odkhcxn/public_html/wp-content/plugins/subscribe-to-comments/subscribe-to-comments.php on line 590
David says:
The FDA posting is a pretty good summary of the evidence (http://www.fda.gov/cder/drug/infopage/mecasermin_rinfabate/default.htm). This page also links to the Italian summary and a statement from the sponsor company. In the FDA’s review of available evidence, Iplex was not significantly better than placebo in any of 5 controlled trials, and in 2 of these it was associated with a numerically higher death rate than placebo (though not statistically significant). Take a close look at the survival curve for the japanese study. The current round of enthusiasm is set of by the sponsor company presenting new uncontrolled data on a small cohort that looks promising.
Named by more than 60 critics as one of the best books of 2010
School Resources
Photos, videos, and more for teachers and students. Learn More →
Book Special Features
Reading group guides, videos, photos, and more. Learn More →
Forthcoming Book
Keep up-to-date on Rebecca's next book. Learn More →
Get in Touch
Use our form for media inquiries, film rights,speaking engagements and to get in touch with Rebecca. Learn More →
The Henrietta Lacks Foundation
The Henrietta Lacks Foundation strives to provide financial assistance to needy individuals who have made important contributions to scientific research without their knowledge or consent.